During the COVID-19 pandemic, Pfizer leveraged Kore.ai’s AI agent platform to deploy a multilingual support system across 17 ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

With a rumored $8m price tag, the Super Bowl ad stakes are high – but the potential brand rewards are massive. How can ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...